Provectus concludes patient recruitment in psoriasis drug Phase 2C trial - Pharmaceutical Business Review

Provectus concludes patient recruitment in psoriasis drug state of matter 2C trial medicine Business Review Provectus Pharmaceuticals has ended patient recruitment in a multi-center, randomized, vehicle controlled state of matter 2C trial evaluating PH-10 as type A treatment for disease of the skin . The establishment has recruited around 90 patients At four sites which include Mount ... Provectus Pharmaceuticals Completes Patient Accrual in Phase 2C Clinical Trial ... EON: Enhanced Online tidings (press release) each 8 news articles » Link To Article